Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands - Takeaways - MDSpire

Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands

  • By

  • Thomas Otten

  • Mirjam Knol

  • Lard Montesano Montessori

  • Pieter de Boer

  • Anneke Steens

  • February 10, 2026

  • 0 min

Share

  • 1

    Invasive meningococcal disease caused by serogroup B (IMD-B) poses significant risks, particularly for infants and adolescents in the Netherlands.

  • 2

    The 4CMenB vaccine is currently licensed for infants and adolescents but is not included in the Dutch National Immunization Program.

  • 3

    Past evaluations deemed IMD-B vaccination not cost-effective due to low incidence and high vaccination costs compared to conventional thresholds.

  • 4

    Recent developments, including new vaccination schedules and increased IMD-B incidence, necessitate reevaluation of vaccination strategies.

  • 5

    A comprehensive analysis is underway to assess the clinical impact and cost-effectiveness of IMD-B vaccination for infants and adolescents in the Netherlands.

Original Source(s)

Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands

  • by Thomas Otten, Mirjam Knol, Lard Montesano Montessori, Pieter de Boer, Anneke Steens

  • February 10, 2026

Related Content

Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population

Using the NASSS–Complexity Assessment Tool to Evaluate the Implementation of “Cadê O Kauê?”: Chat-Story Intervention for Youth Participation in Mental Health Promotion in Brazil

Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report